Previous 10 | Next 10 |
- Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid ( BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin (≥ 30%) in nearly 1 out of 3 of patients - - In patients with metabolic syndrome NEXLETOL lowered hemogl...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Esperion Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Esperion Therapeutics, inc (NASDAQ: ESPR) Q3 2021 Earnings Call Nov 2, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics, inc (ESPR) Q3 2021 Earnings Call Transcrip...
Esperion Therapeutics, Inc. (ESPR) Q3 2021 Results Conference Call November 02, 2021 08:00 AM ET Company Participants Ben Church - Investor Relations & Corporate Communications Sheldon Koenig - President & Chief Executive Officer Rick Bartram - Chief Financial Officer Dr. Joanne Foody...
Esperion's (NASDAQ:ESPR) Q3 2021 earnings beat was helped by sales of its two cholesterol-lowering drugs. The company reported net product revenue in the quarter composed of sales of Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) of $10.9M, up from $4.8M in th...
Esperion Therapeutics (NASDAQ:ESPR): Q3 GAAP EPS of -$2.62 beats by $0.22. Revenue of $14.41M (+276.2% Y/Y) beats by $2.52M. Press Release For further details see: Esperion Therapeutics EPS beats by $0.22, beats on revenue
– Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth – – Unprecedented CLEAR Outcomes Study Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Acc...
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021. AHA Scientific Sessions 2021 Bempedoic Acid ...
Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q3 earnings results on Tuesday, November 2nd, before market open. The consensus EPS Estimate is -$2.80 and the consensus Revenue Estimate is $11.89M (+210.4% Y/Y). Last month, Seeking Alpha contributor Biologics argued that "th...
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Esperion team and our directors, I am very pleased to w...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...